KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash from Financing Activities (2016 - 2026)

Gsk has reported Cash from Financing Activities over the past 18 years, most recently at $366.7 million for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 66.07% year-over-year to $366.7 million; the TTM value through Mar 2026 reached -$3.1 billion, up 23.14%, while the annual FY2025 figure was -$4.9 billion, 19.19% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was $366.7 million at Gsk, up from -$1.1 billion in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $10.7 billion in Q1 2022 and troughed at -$3.4 billion in Q4 2024.
  • A 5-year average of $1.1 billion and a median of -$356.2 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: soared 663.85% in 2022 and later tumbled 852.69% in 2024.
  • Year by year, Cash from Financing Activities stood at $4.1 billion in 2022, then plummeted by 108.71% to -$356.2 million in 2023, then plummeted by 852.69% to -$3.4 billion in 2024, then soared by 66.45% to -$1.1 billion in 2025, then skyrocketed by 132.21% to $366.7 million in 2026.
  • Business Quant data shows Cash from Financing Activities for GSK at $366.7 million in Q1 2026, -$1.1 billion in Q4 2025, and $1.1 billion in Q1 2025.